HCV = hepatitis C virus; HR = hazard ratio; IBD = inflammatory bowel disease; IBS = irritable bowel syndrome; OR = odds ratio; QOL = quality of life; SSA/P = sessile serrated adenoma/polyp; TCA = tricyclic antidepressant; UC = ulcerative colitis.
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A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis Authors: Miehlke S et al. Summary: Adults with active eosinophilic oesophagitis were randomised to receive 14 days of treatment with two effervescent orodispersible budesonide 1mg tablets (n=19) or two 2mg tablets (n=19), budesonide viscous suspension 2×5mL (0.4 mg/ mL; n=19) or placebo (n=19) daily in a double-blind, double-dummy manner and were followed for 2 weeks. Compared with placebo, the budesonide 1mg and 2mg effervescent tablets and the suspension were associated with significantly greater histological remission rates (mean of <16 eosinophils per mm 2 high-power field; primary endpoint; 100%, 94.7% and 94.7%, respectively, vs. 0% [p<0.0001]) and significantly greater improvements in total endoscopic intensity score. All groups had improvements in dysphagia after treatment, but this was only sustained in the budesonide 1mg effervescent tablet recipients compared with placebo (p=0.0196). No serious adverse events were recorded, and two budesonide recipients in each group developed local fungal infections. Eighty percent of participants preferred the effervescent tablets.
Comment: Eosinophilic oesophagitis is a chronic condition with significant symptoms and increasing incidence worldwide. While oral budesonide has been shown to be effective, no oral formulation per se is currently available outside clinical trials or from inhalants. The current study addressed this by testing orally dispersible budesonide in tablet form at 1mg or 2mg twice a day or as an oral liquid as compared with placebo. Budesonide was highly effective in inducing histological remission and improved endoscopic intensity scores. Oral fungal infections occurred in two patients, and the effervescent tablet form was preferred by patients over the liquid. Notably, the lower dose (1mg) tablet achieved a 100% remission rate. The study highlights the difficulty in terms of assessing symptoms in response to treatment and the lack of a validated scoring system, and as a matter of fact, symptoms improved even in the placebo group. Overall, this study, which is the largest randomised clinical trial in eosinophilic oesophagitis so far, clearly shows the potency of oral budesonide in inducing remission. However, there are still substantial questions around long-term treatment, symptom resolution and maintaining remission in patients with eosinophilic oesophagitis.
Reference: Gut 2016;65(3):390-9 Abstract
Clinical and endoscopic predictors of cytological dysplasia or cancer in a prospective multicentre study of large sessile serrated adenomas/polyps Authors: Burgess NG et al.
Summary:
This was an analysis of prospective data on 268 SSA/Ps (sessile serrated adenomas/polyps) measuring ≥20mm, identified in 207/1546 patients (13.4%), of which 32.4% were SSA/Ps with cytological dysplasia; 3.9% were cancerous. A multivariable analysis revealed associations between SSA/Ps with cytological dysplasia and each increasing decade of age (OR 1.69 [95% CI 1.19-2.40]), each 10mm increase in lesion size (1.90 [1.30-2.78]), an adenomatous pit pattern (Kudo III, IV or V; ) and any 0-Is component within an SSA/P (3.10 [1. 19-8.12] ). An adenomatous pit pattern was more likely in conventional type dysplasia than serrated dysplasia. Presence of high-grade dysplasia or cancer was seen in 7.2%, with associations with each decade increase in age (OR 2.0 [95% CI 1.13-3.56]) and any Paris 0-Is component (10.2 [3.18-32.4 
]).
Comment: SSA/Ps account for 20-30% of sporadic cancers. As they are often difficult to detect, SSA/Ps remain an important risk factor for interval cancers, which remains 5-7% after colonoscopy. Additionally, SSA/Ps are often only partially resected. The current study addressed the lack of information on clinical and endoscopic characteristics of SSA/Ps with cytological dysplasia. Dysplasia in SSA/Ps may assume serrated or conventional morphology, which can result in underappreciation of the underlying lesion. In this large prospective cohort study of 268 large SSA/Ps (>20mm), dysplasia was found in 32.4%. Submucosal invasive cancer was found in 3.9%. Dysplasia was associated with age, lesion size, adenomatous pit pattern (Kudo III, IV or V) and a Paris class 0-Is nodular component, whereas the main risk factors for high-grade dysplasia were age and 0-Is nodular component. This highlights the importance of careful assessment of flat polyps and vigilance when encountering serrated adenomas and interpreting pathology results. Presence of serrated lesions, particularly those with dysplasia, need to be taken into consideration when planning surveillance intervals.
Reference: Gut 2016;65(3):437-46 Abstract
Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up Authors: Bryant RV et al.
Summary:
These researchers compared histological remission (Truelove and Richards' index) with endoscopic mucosal healing (Baron score ≤1) for predicting UC outcomes in 91 patients with established disease at baseline; median follow-up was 72 months. There was moderate concordance between endoscopic and histological remission (κ=0.56 [95% CI 0.36-0.77]); inflammation persisted in 24% of patients despite endoscopic remission. Corticosteroid use and hospitalisation for acute, severe colitis were predicted by histological remission (respective HRs 0.42 [95% CI 0.2-0.9] and 0.21 [0.1-0.7]), but not endoscopic mucosal healing (0.86 [0.5-1.7] and 0.83 [0.3-2.4]).
Comment: Endoscopic mucosal healing, i.e. complete resolution of endoscopically visible inflammation, is a well-established treatment goal in UC as it is associated with clinical remission and lower rates of colectomy. However, inflammation is often still present on histology even in the context of endoscopic and clinical remission; only limited uncontrolled data are available regarding the role of histological remission for patient outcomes in UC. In this study 91 patients with UC were followed over 6 years. The study included 27% with proctitis, 49% with distal disease and 21% with extensive disease. At baseline, 53% of patients were on 5-aminosalicylic acid agents alone and 3% were on antitumour necrosis factor therapy. Not unexpectedly, there was only moderate agreement between clinical, endoscopic and histological measures of disease activity. However, only histological remission predicted reduced future corticosteroid requirements (HR 0.42). Twenty-two percent of study participants required hospital admission for acute, severe colitis with histological remission predicting reduced rates of hospitalisations in contrast to endoscopic remission, which did not. Neither clinical, endoscopic nor histological remission predicted colectomy. However, the study was likely underpowered given that the colectomy rate was only 12%. Overall, this study suggests that revisiting histological remission as a treatment endpoint may be a useful and readily available opportunity to better identify patients at risk of poor outcomes and therefore requiring more intense therapy.
Reference: Gut 2016;65(3):408-14 Abstract
Clostridium difficile associated risk of death score (CARDS): a novel severity score to predict mortality among hospitalised patients with C. difficile infection Authors: Kassam Z et al.
Summary:
A novel Clostridium difficile infection risk score (CARDS) for predicting mortality was developed using 2011 US data from 374,747 cases of C. difficile infection among 77,776 hospitalisations; the in-hospital mortality rate was 8%. A multivariate analysis identified the following eight severity score predictors: age, cardiopulmonary disease, malignancy, diabetes, IBD, acute renal failure, liver disease and ICU admission. Weighting for these predictors ranged from -1 for diabetes to 5 for ICU admission. A significant increase in mortality was seen as CARDS increased. CARDS ranged from 1 (1.2% mortality) to 18 (100% mortality). Validation using data from the same database but 1 year earlier yielded equal performance.
Comment: C. difficile infection has become one of the most common healthcare associated infections in the Western world, with C. difficile infection incidence increasing dramatically in the last few years. C. difficile infection severity is a major determinant of treatment efficacy, but only limited data are available on C. difficile infection-specific severity metrics and often only from small cohorts. The current study used the US 2011 Nationwide Inpatient Sample captured from 1049 hospitals in 46 states. They identified 77,776 cases with C. difficile infection, and multivariate regression was used to identify independent risk factors to create the CARDS (C. difficile-associated risk of death score): age, cardiopulmonary disease, malignancy, diabetes mellitus, IBD and acute renal failure and ICU admission. While ICU admission and renal failure were the strongest predictors, diabetes was associated with a decrease in mortality. Mortality increased significantly with increasing CARDS score from 1.2% at CARDS=0 to 100% with CARDS=18 (maximum score). The score was subsequently validated in a second cohort. The CARDS score may prove helpful in terms of identifying patients at risk of poor outcome, used by hospitals to track the severity of presentations and assist with studies as a validated assessment tool for C. difficile infection severity.
Reference: Aliment Pharmacol Ther 2016;43 (6) . This study was also summarised by the journal's Section Editors.
Comment: Statins have been the mainstay for treatment of hyperlipidaemia and primary and secondary prevention of coronary artery disease. It has been previously shown that statins may reduce portal pressure in patients with cirrhosis (Gastroenterology 2009), but may also exert anti-inflammatory, antifibrotic, and antineoplastic effects. The current retrospective study addressed the impact of statin use on decompensation and survival times in patients with compensated cirrhosis using the Department of Veterans Affairs HCV Clinical Case Registry; 685 new statin users were matched in a 1:5 ratio with 2062 nonusers. Statin use was associated with lower risk for decompensation and death. Notably, this association persisted after correction for age, FIB-4 index score, serum albumin level, model for end-stage liver disease and Child-Turcotte-Pugh score and death. Further detailed analysis also showed associations with lower risk of variceal haemorrhage and ascites as well as a lower risk for hepatocellular carcinoma. While the influence of other concomitant factors such as alcohol use cannot be excluded and this study was retrospective in design and not placebo-controlled, this is further evidence that statin use in HCV-related cirrhosis is associated with decreased disease progression, death and hepatocellular carcinoma. : Gastroenterology 2016; 150(2):291-4 & 430-40 Abstract Editorial Outcomes of esophageal dilation in eosinophilic esophagitis: safety, efficacy, and persistence of the fibrostenotic phenotype Authors: Runge TM et al. Summary: The safety and long-term efficacy of oesophageal dilatation were investigated in a large retrospective cohort of 509 patients with eosinophilic oesophagitis; 164 patients underwent 486 dilatation procedures, with 95 requiring repeated procedures (75% within 1 year). Compared with patients who did not undergo dilatation, those who did had a longer prediagnosis duration of symptoms (11.1 vs. 5.4 years [p<0.001]). Smaller baseline oesophageal diameter was the only predictor of needing multiple dilatations. There were no major bleeds, perforations or deaths, and the overall complication rate was 5%, mostly related to postprocedural pain.
Reference
Comment: While oral steroids have proven efficacy in inducing remission in eosinophilic oesophagitis, dilatation is often considered in the context of a stricture for rapid symptom relief. However, while oesophageal dilatation for symptomatic eosinophilic oesophagitis and particularly eosinophilic oesophagitis-related strictures is performed not infrequently, the actual long-term outcomes are not well studied. The current retrospective study included 164 patients with eosinophilic oesophagitis undergoing 486 dilatations and 345 patients with eosinophilic oesophagitis not receiving dilatation therapy recruited over 12 years. In keeping with the concept that fibrosis due to chronic inflammation plays an important part in the structuring in eosinophilic oesophagitis, patients requiring dilatation had been symptomatic for a significantly longer time than this not needing endoscopic therapy (11.1 vs. 5.4 years). Symptoms associated with need for dilatation were dysphagia, food impaction and absence of heartburn or abdominal pain. Endoscopic factors were presence of rings and abnormal baseline endoscopy. In general, dilatation was tolerated well with a 5% complication rate and no major bleeds, perforations or deaths. Fifty-eight percent of dilated patients required a second dilatation with 75% of these requiring it within the first 12 months. Thus, overall, dilatation of eosinophilic oesophagitis was safe and resulted in good symptom relief, albeit with the need for repeat procedures in the majority of patients.
Reference: Am J Gastroenterology 2016; 111(2):206-13 Abstract Imipramine for treatment of esophageal hypersensitivity and functional heartburn Authors: Limsrivilai J et al. Summary: Patients with established oesophageal hypersensitivity or functional heartburn were randomised to receive imipramine 25mg (n=43) or placebo (n=40) once daily for 8 weeks. There was no difference between imipramine and placebo recipients for >50% reductions in gastroesophageal reflux disease scores (primary endpoint) in intent-to-treat and per-protocol analyses (37.2% vs. 37.5%; , respectively); similar results were seen in subgroup analyses assessing oesophageal hypersensitivity and functional heartburn separately. Imipramine significantly improved QOL on the 36-Item Short Form Health Survey versus placebo in the per-protocol analysis (p=0.048), but not in the intent-to-treat analysis (p=0.26). Overall adverse events were similar between the groups, but constipation was more common among imipramine than placebo recipients (51.2 vs. 22.5% [p=0.01]). The findings of this study were also discussed in an editorial in the same issue of the journal.
Comment: Patients with oesophageal hypersensitivity and functional heartburn respond poorly to therapy with proton-pump inhibitors. While TCAs (tricyclic antidepressants) have been recommended in this context, placebo-controlled data for TCAs are limited. In the current study, the TCA imipramine showed a similar symptom rate to placebo with ~37% of patients achieving a >50% decrease in oesophageal symptoms. However, QOL scores were more likely to improve with imipramine. Similar results have been observed in a large randomised clinical trial in IBS where the TCA desipramine was compared with placebo (Gastroenterology 2003). While desipramine improved 'satisfaction with treatment' score, no improvement was seen with actual IBS symptoms; i.e. while symptoms remained stable, coping with symptoms became easier. Thus, the real aim for introducing TCAs in this context needs to be better QOL and not necessarily immediate symptom relief. Understanding this and more importantly communicating this to our patients is crucial to manage expectations and compliance.
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Relationship between microbiota of the colonic mucosa vs feces and symptoms, colonic transit, and methane production in female patients with chronic constipation Authors: Parthasarathy G et al. Summary: These researchers performed 16S ribosomal RNA gene sequencing on microbiota samples obtained from the sigmoid colonic mucosa and faeces of 25 women with chronic constipation and 25 healthy control women. Slow colonic transit was seen in 14 of the women with chronic constipation. The colonic mucosal microbiota profiles differed significantly between the women with constipation and the controls (p<0.05); the overall composition was associated with constipation independent of colonic transit (p<0.05) and discriminated between the two groups with 94% accuracy. Women with constipation had a greater abundance of Bacteroidetes spp. in their colonic mucosal microbiota. The faecal microbiota profile was associated with colonic transit when not adjusted for constipation, age, body mass index and diet; Firmicutes (Faecalibacterium, Lactococcus and Roseburia) spp. correlated with faster colonic transit. Methane production showed an association with faecal microbiota composition, but not with constipation or colonic transit. In their discussion of the topic, the authors of an editorial in the same issue of the journal note that these findings reflect the complex relationships between colonic motility and constipation.
Comment: Constipation whether idiopathic or related to other medical problems or a long list of commonly prescribed medications is a common chronic condition with significant impact on patient QOL. Furthermore, chronic constipation often results in chronic laxative use, which brings with its own significant problems. While alterations of gut microbiota have been described in IBS with predominant constipation, the results remain inconsistent and sometime contradict each other. Further complicating matters is the poorly understood relationship between faecal and mucosal microbiome. The current study compared faecal and mucosal microbiome in healthy subjects and patients with idiopathic constipation. The mucosal microbiome differed between constipated patients and controls. Composition of the microbiome was associated with constipation, but unrelated to colonic transit and allowed discrimination between patients and controls. While certain genera were more common in mucosal mucosa of patients with constipation, specific faecal genera were associated with transit time as well as methane production. Overall this study demonstrates strong relationships between gut microbiota and bowel symptoms in patients with chronic constipation, but does not explain necessarily cause and effect. Further studies will be required to better understand this relationship and whether modification thereof will result in symptom improvement in these chronically ill patients. : Gastroenterology 2016; 150(2):300-3 & 367-79 Abstract Editorial Classifying back pain and peripheral joint complaints in inflammatory bowel disease patients Authors: van Erp SJ et al. Summary: This research prospectively followed patients with IBD, including 13 with chronic back pain, 80 with peripheral joint complaints, 62 with axial/peripheral joint complaints and 100 controls with no such complaints. Factors independently associated with the presence of joint or back pain were smoking, female gender and IBD disease activity. Criteria for axial/peripheral spondyloarthritis were met by 12.3% of patients, with 9.7% receiving a rheumatological diagnosis of arthritis. Most patients reported stable joint/back pain during the 12-month follow-up period.
Reference
